Skip to main content
Unchecking box will stop auto data updates
TSX Real-Time Last Sale CAD
Today's Change
Volume
Price Quote as of

Today's Trading

Day Low 3.50
Day High 3.60
Open:3.51
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

More stories below advertisement

Description
AEterna Zentaris Inc is a specialty biopharmaceutical company. It is involved in development and commercialization of novel pharmaceutical therapies, drug development activities and promotion of products for others in oncology, endocrinology and women's health. The company focuses on the acquisition of licenses to products that are relevant to their therapeutic areas of focus. Its primary product is Apifiny. It is developing Macrilen, Zoptrex and AEZS drugs in the pipeline.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Morningstar, including Income Statements,Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Buy/Hold Recommendations, Earnings Surprises, Estimates and Recommendations History.

Stock Reports +

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

StockCalc Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

Latest Press Releases

Aeterna Zentaris Provides Corporate Update
GlobeNewswire - Thu Jun 6, 1:07PM CDT
GlobeNewswire - CMTX
Thu Jun 6, 1:07PM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) today announced that it is reducing the size of its German workforce and operations to more closely reflect the Company's ongoing commercial activities in Frankfurt.
Aeterna Zentaris Announces Results of Annual and Special Shareholders' Meeting
GlobeNewswire - Wed May 8, 5:05PM CDT
GlobeNewswire - CMTX
Wed May 8, 5:05PM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) announced today at its annual and special shareholders' meeting held on May 8, 2019, that the individuals noted below were elected as directors of the Company. The report on proxies provided by the Company's transfer agent indicated the following:
Aeterna Zentaris Reports First Quarter 2019 Financial and Operating Results
GlobeNewswire - Tue May 7, 4:13PM CDT
GlobeNewswire - CMTX
Tue May 7, 4:13PM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) today reported its financial and operating results for the first quarter ended March 31, 2019.
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 2.64 +33.33% increase
on 06/07/19
Period Open:4.21
Price movement based on the high, low and last over the given period.
4.36 -19.27% decrease
on 05/29/19
-0.69 (-16.39%) decrease
since 05/24/19
3-Month 2.64 +33.33% increase
on 06/07/19
Period Open:5.57
Price movement based on the high, low and last over the given period.
7.43 -52.62% decrease
on 04/05/19
-2.05 (-36.80%) decrease
since 03/22/19
52-Week 1.68 +109.52% increase
on 10/30/18
Period Open:2.82
Price movement based on the high, low and last over the given period.
7.43 -52.62% decrease
on 04/05/19
+0.70 (+24.82%) increase
since 06/22/18

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2019.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).